SCHEMBL12467412

SCHEMBL12467412

CCc1cc(Cl)cnc1OC

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C9 P11712 2/20 0.43
LMNA P02545 1/20 0.43
TSHR P16473 1/20 0.43
APEX1 P27695 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
MAPK1 P28482 1/20 0.38
BCHE P06276 1/20 0.37
LIPE Q05469 1/20 0.37
FFAR4 Q5NUL3 1/20 0.37
SLC6A2 P23975 4/20 0.36
SLC6A4 P31645 4/20 0.36
L3MBTL1 Q9Y468 1/20 0.35
SLC13A5 Q86YT5 2/20 0.35
SLC13A2 Q13183 1/20 0.35
SLC13A3 Q8WWT9 1/20 0.35
SLC6A3 Q01959 1/20 0.35
GPBAR1 Q8TDU6 1/20 0.33
CCR4 P51679 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1477059 0.85 CYP2C9 (0.43) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL5783160 0.83 CYP2C9 (0.42) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL25117788 0.83 CYP2C9 (0.42) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL21706076 0.80 ALOX5 (0.41) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL28942777 0.80 LMNA (0.43) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL30364398 0.80 LMNA (0.43) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL28959989 0.79 KMT2A (0.39) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL32689790 0.79 PLAU (0.55) LMNAFFAR4L3MBTL1SLC13A5SLC13A2
SCHEMBL25229051 0.79 CYP2C9 (0.36) CYP2C9LMNATSHRAPEX1SMN1; SMN2
SCHEMBL12093547 0.78 SLC13A5 (0.51) CYP2C9SMN1; SMN2L3MBTL1SLC13A5SLC13A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4638438-A1 ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF Xinthera, Inc. (US) 2025-10-29 EP disclosed
US-20240279214-A1 ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF XINTHERA, INC. 2024-08-22 US disclosed
WO-2024138042-A1 ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF XINTHERA, INC. (US) 2024-06-27 WO disclosed
WO-2024138042-A1 ALPHA4 BETA7 INTEGRIN ANTAGONISTS AND USES THEREOF XINTHERA, INC. (US) 2024-06-27 WO disclosed
WO-2023218195-A1 GCN2 INHIBITORR IP2IPO INNOVATIONS LIMITED (GB) 2023-11-16 WO disclosed
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS HIBERCELL, INC. 2022-12-08 US disclosed
US-10807968-B2 Substituted 2-(het)arylimidazolylcarboxyamides as pesticides BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-10-20 US disclosed
US-20200048221-A1 SUBSTITUTED 2-(HET)ARYLIMIDAZOLYLCARBOXYAMIDES AS PESTICIDES BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) 2020-02-13 US disclosed
EP-2366704-B1 Inhibitors of serine proteases VERTEX PHARMA (US) 2013-10-23 EP disclosed
US-20100120762-A1 Triazine derivatives as inhibitors of phosphodiesterases WYETH (US) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200048221-A1 SUBSTITUTED 2-(HET)ARYLIMIDAZOLYLCARBOXYAMIDES AS PESTICIDES DDT, CYP4X1, CYP4Z1 CYP2C9 9/4885LMNA 1841/4885TSHR 1122/4885
US-10807968-B2 Substituted 2-(het)arylimidazolylcarboxyamides as pesticides DDT, CYP4X1, CYP4Z1 CYP2C9 9/4885LMNA 1841/4885TSHR 1122/4885
US-20240279214-A1 ALPHA4 BETA7 INEGRIN ANTAGONISTS AND USES THEREOF ITGB7, ITGB4, ITGA4 CYP2C9 3900/4885LMNA 3808/4885TSHR 3111/4885
US-20220388964-A1 (AZA)INDAZOLYL-ARYL SULFONAMIDE AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS EIF2AK4, GCN1, GNAI2 CYP2C9 1054/4885LMNA 3719/4885TSHR 4280/4885
US-20100120762-A1 Triazine derivatives as inhibitors of phosphodiesterases PDE2A, PDE5A, PDE12 CYP2C9 925/4885LMNA 4521/4885TSHR 1388/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.